Welcome to the e-CCO Library!

search
Search by: 
Year: Category: Sub Type:
DOP01: Exclusive enteral nutrition for treatment of Adult Crohn's Disease
Year: 2020
Source: ECCO'20 Vienna
Authors: Liz Purcell
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP020: Higher vedolizumab levels are associated with deep remission in patients with Crohn’s Disease and Ulcerative Colitis on maintenance therapy with vedolizumab
Year: 2017
Source: ECCO'17 Barcelona
Authors: Yarur A.
Patient reported outcomes, Therapeutic drug monotoring, Pharmacokinetics, Treat to tatrget, Vedolizumab
Files: 1
DOP020: Prediction of clinical and endoscopic remission after autologous stem cell transplantation in treatment refractory Crohn’s disease: pooled results from the ASTIC trial
Year: 2016
Source: ECCO'16 DOP
Authors: Lindsay J.
stem cell transplantation/therapy, clinical trials, Crohn's Disease
Files: 1
DOP020:Thiopurine monotherapy still has a place in the treatment of patients with Mild-to-Moderate Crohn’s Disease in the biological era
Year: 2018
Source: ECCO'18 Vienna
Authors: Verstockt Bram
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP021: Immunosuppressive and anti-TNF treatment is associated with a lower risk of migration from B1-to-B3-stage in Crohn’s Disease: 10-year-follow-up data from the Swiss IBD cohort study
Year: 2018
Source: ECCO'18 Vienna
Authors: Biedermann Luc
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP021: Long term efficacy of autologous haematopoietic stem cells transplantation for refractory Crohn’s disease: ten years of Milan experience without CD34+ cell selection.
Year: 2016
Source: ECCO'16 DOP
Authors: Cassinotti A.
stem cell transplantation/therapy, clinical trials, Crohn's Disease
Files: 1
DOP021: Long-term effectiveness and safety of vedolizumab in patients with Crohn’s Disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Vermeire S.
Vedolizumab
Files: 1
DOP022: Tacrolimus suppositories as induction therapy for refractory ulcerative proctitis: A randomised controlled trial
Year: 2018
Source: ECCO'18 Vienna
Authors: Kreijne Joany E.
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP022: Targeting Immune Cell Metabolism: LYC-30937, A Novel Therapeutic Approach for Inflammatory Bowel Disease
Year: 2016
Source: ECCO'16 DOP
Authors: Higgins P.
clinical trial
Files: 1
DOP022: Vedolizumab (VDZ) and anti-α treatment effectiveness in patients with IBD treated in Germany: A retrospective chart review
Year: 2017
Source: ECCO'17 Barcelona
Authors: Ehehalt R.
Crohn's disease, Anti-TNF agents,Vedolizumab
Files: 1
DOP023: Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active Ulcerative Colitis: Results from the US VICTORY consortium
Year: 2017
Source: ECCO'17 Barcelona
Authors: Dulai P.
Ulcerative colitis, Patient reported outcomes, Vedolizumab
Files: 1
DOP023: Safety and efficacy of a novel i.v. targeted pegylated liposomal prednisolone (Nanocort): results from a phase 2a study in patients with active ulcerative colitis
Year: 2016
Source: ECCO'16 DOP
Authors: Vermeire S.
Ulcerative Colitis, corticosteroids, clinical trial
Files: 1
DOP024: Electrical vagus nerve stimulation as an innovative treatment in inflammatory bowel diseases
Year: 2016
Source: ECCO'16 DOP
Authors: Bonaz B.
Crohn's Disease
Files: 1
DOP024: Tofacitinib achieves symptomatic improvement within three days in moderately to severely active Ulcerative Colitis, regardless of prior tumour necrosis factor inhibitor treatment status: Results from OCTAVE induction 1 2
Year: 2018
Source: ECCO'18 Vienna
Authors: Reinisch Walter
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP024: Vedolizumab clinical and post-marketing safety experience of opportunistic infections
Year: 2017
Source: ECCO'17 Barcelona
Authors: Ng S.
Concomitant infections, Vedolizumab
Files: 1
DOP025: Clinical response to anti-MMP9 antibody (GS-5745) is accompanied by histologic improvement in ulcerative colitis
Year: 2016
Source: ECCO'16 DOP
Authors: Levesque B.
histological healing
Files: 1
DOP025: Efficacy of vedolizumab on extraintestinal manifestation in patients with Inflammatory Bowel Disease: A post-hoc analysis of the OBSERV-IBD cohort from the GETAID
Year: 2017
Source: ECCO'17 Barcelona
Authors: Tadbiri S.
Vedolizumab, Arthralgia, Perianal disease, other extraintestinal manifestations
Files: 1
DOP025: Tofacitinib for the treatment of Ulcerative Colitis: Analysis of malignancy rates from the OCTAVE clinical programme
Year: 2018
Source: ECCO'18 Vienna
Authors: Rogler Gerhard
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP026: Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with Ulcerative Colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: Results from OCTAVE open
Year: 2018
Source: ECCO'18 Vienna
Authors: Armuzzi Alessandro
Created: Tuesday, 8 May 2018, 11:36 AM
Files: 1
DOP026: Sustained remission with vedolizumab in patients with Moderately to Severely active Ulcerative Colitis: A GEMINI 1 post hoc analysis of Week 14 remitters
Year: 2017
Source: ECCO'17 Barcelona
Authors: Stallmach A.
Ulcerative colitis, Vedolizumab
Files: 1